UnitedHealthcare sets monthly GLP-1 quantity limits starting September 1
The list sets how much of each GLP-1 drug UnitedHealthcare commercial plans will cover in a given period, which can affect refill timing and 90-day supplies.
UnitedHealthcare has published an updated list of quantity limits for GLP-1 medications that takes effect September 1, 2026, capping how much of each drug is covered in a set period. The document, dated August 21, 2026, allows 4 Wegovy pens, 1 Ozempic pen, 4 Zepbound autoinjectors or vials, 1 Zepbound KwikPen, 4 Mounjaro pens and 5 Saxenda pens per monthly fill [1].
The document is titled "Quantity Duration (QD) Limits per Duration Medication List" and applies to UnitedHealthcare commercial plans. It describes supply limits as the maximum quantity of a drug that is covered in a copay or within a specified timeframe [1].
The caps differ by product. For the Wegovy tablets listed, the limit is 30 tablets, with a separate limit of 60 tablets per 365 days for the 1.5 mg, 4 mg and 9 mg strengths [1]. Ozempic and the Zepbound KwikPen are capped at one unit per fill, while Wegovy, the Zepbound autoinjectors or vials, and Mounjaro are capped at four, and Saxenda at five [1]. The list does not explain why the limits differ across products.
The list also states that two one-month fills are required before a three-month fill becomes available [1].
Two caveats are printed on the document. Inclusion in the list does not indicate that a drug is covered by a particular plan, and any drug may be subject to other requirements, including "Exclude at Launch" and "Review at Launch" [1]. Whether any of these GLP-1 figures changed from the previous version of the list has not been reported. The list also does not address dosing or how a prescriber's instructions relate to the covered quantity.
Why it matters for patients
A quantity limit is not the same as a coverage decision. It sets the maximum amount of a drug a plan will pay toward in a copay or over a stated period [1]. For people filling GLP-1 prescriptions, that means the number of pens, autoinjectors, vials or tablets a pharmacy can dispense at one time can be restricted, even if the drug itself remains on the plan's list of covered medicines.
The rule requiring two one-month fills before a three-month fill can affect people who prefer to pick up a 90-day supply, because the longer fill is not available until the shorter ones have been filled [1]. Because coverage varies by plan and the list says other requirements may apply [1], patients who want to know what their own plan covers would need to check their specific benefit details. The list does not state copays, prior authorization rules, or what a patient would pay out of pocket.
It also does not say how the limits were set, whether they match the labeled dosing for each product, or what happens if a prescription calls for a quantity above the cap. Those details have not been disclosed.
What happens next
The updated list carries a September 1, 2026 effective date and was last updated August 21, 2026 [1]. It covers a long list of medications beyond GLP-1s, each with its own supply limit and an indication of whether overrides are allowed [1]. Anyone with questions about how the limits apply to a specific prescription would need to confirm details with their plan or pharmacy, since the document itself notes that inclusion on the list does not mean a drug is covered [1].
Sources
Semaglutides.org provides information only, not medical advice. Talk to a licensed provider about your own care before making changes. Some telehealth links are affiliate links and are labeled where they appear.